Page last updated: 2024-10-28

fasudil and 2019 Novel Coronavirus Disease

fasudil has been researched along with 2019 Novel Coronavirus Disease in 2 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Xia, L1
Yuan, LZ1
Hu, YH1
Liu, JY1
Hu, GS1
Qi, RY1
Zhang, TY1
Xiong, HL1
Zheng, ZZ1
Lin, HW1
Zhang, JM1
Yu, C1
Zhou, M1
Ma, J1
Cheng, T1
Chen, RR1
Guan, Y1
Xia, NS1
Liu, W1
Sykes, RA1
Neves, KB1
Alves-Lopes, R1
Caputo, I1
Fallon, K1
Jamieson, NB1
Kamdar, A1
Legrini, A1
Leslie, H1
McIntosh, A1
McConnachie, A1
Morrow, A1
McFarlane, RW1
Mangion, K1
McAbney, J1
Montezano, AC1
Touyz, RM1
Wood, C1
Berry, C1

Other Studies

2 other studies available for fasudil and 2019 Novel Coronavirus Disease

ArticleYear
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
    Cellular & molecular immunology, 2023, Volume: 20, Issue:4

    Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate;

2023
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy.
    European heart journal. Cardiovascular pharmacotherapy, 2023, 06-02, Volume: 9, Issue:4

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Cardiovascular Diseases; COVID-1

2023